NovAccess Global Inc. (XSNX)
NovAccess Global Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York, NY, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $6,165. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 2.80 implies it has historically moved more than the broad market.
Operating as a biopharmaceutical firm, NovAccess Global Inc. focuses on developing innovative immunotherapies to treat individuals with brain tumors across the United States. Their primary expertise is in pioneering research that leverages a patient's own immune system to target and eliminate cancerous cells. The company, founded in 1997, has its headquarters situated in Chesterland, Ohio.
NovAccess Global Inc. is most often compared with the following Healthcare names: